Table 2 Analysis of variance on the three selected groups
Not admitted (n = 131; 20.2%) | Admitted without event (n = 421; 65.2%) | Admitted with event (n = 94; 14.6%) | P | |
|---|---|---|---|---|
Age (years) | 51.0 ± 12.3 | 65.6 ± 14.3* | 75.1 ± 10.6#° | < 0.001 |
Male gender | 67 (51.1%) | 260 (61.8%) | 56 (59.6%) | 0.097 |
Creatinine (mg/dl) | 0.79 [0.67–0.91] | 0.95 [0.79–1.11]* | 1.01 [0.8–1.46]# | < 0.001 |
Platelets (/mmc) | 236.79 ± 136.01 | 244.93 ± 108.65 | 215.55 ± 104.54 | 0.106 |
MR-proADM (nmol/L) | 0.57 [0.48–0.70] | 0.91 [0.70 -1.26]* | 1.345 [0.98–2.22]#° | < 0.001 |
WBC (/mmc) | 5.30 [4.25–6.50] | 6.24 [4.42–8.76] * | 7.63 [5.20–11.04]#° | < 0.001 |
Lymphocytes (/mmc) | 1.20 [0.80–1.70] | 0.88 [0.62–1.20]* | 0.77 [0.47–1.05]#° | < 0.001 |
LDH (U/L) | 499 [418–621] | 553 [418–694]* | 735 [544–971]#° | < 0.001 |
Procalcitonin (mg/dl) | 0.05 [0.03–0.08] | 0.07 [0.04–0.14]* | 0.13 [0.07–0.45]#° | < 0.001 |
CRP (mg/L) | 20.10 [9.80–44.75] | 59.45 [19.60–99.56]* | 87.22 [48.27–149.70]#° | < 0.001 |
D-Dimer (ng/ml) | 493 [350–676] | 640 [428–1132]* | 969 [516–1777]#° | < 0.001 |
Cardiovascular disease | 4 (3.1%) | 130 (30.9%)* | 49 (52.1%)#° | < 0.001 |
Chronic respiratory disease | 8 (6.1%) | 71 (16.9%)* | 28 (29.8%)#° | < 0.001 |
Diabetes | 12 (9.2%) | 28 (6.7%) | 12 (12.8%) | 0.125 |
Chronic kidney disease | 0 (0.0%) | 37 (8.8%) * | 19 (20.2%)#° | < 0.001 |
Malignancy | 4 (3.1%) | 43 (10.2%) | 13 (13.8%)# | 0.012 |
Hypertension | 23 (17.6%) | 209 (49.6%) * | 59 (62.8%)# | < 0.001 |
SOFA score | 0 [0–1] | 3 [2–4]* | 4 [2–5]#° | < 0.001 |
NEWS2 score | 0 [0–0] | 1 [0–3]* | 2 [0–4]# | < 0.001 |